These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26576719)

  • 1. Designing liposomal adjuvants for the next generation of vaccines.
    Perrie Y; Crofts F; Devitt A; Griffiths HR; Kastner E; Nadella V
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):85-96. PubMed ID: 26576719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.
    Perrie Y; Kastner E; Kaur R; Wilkinson A; Ingham AJ
    Hum Vaccin Immunother; 2013 Jun; 9(6):1374-81. PubMed ID: 23584249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.
    Korsholm KS; Andersen PL; Christensen D
    Expert Rev Vaccines; 2012 May; 11(5):561-77. PubMed ID: 22827242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Rosenkrands I; Lindenstrøm T; Andersen P; Agger EM
    Expert Rev Vaccines; 2007 Oct; 6(5):785-96. PubMed ID: 17931158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing Methods for Liposome Adjuvants.
    Perrie Y; Kastner E; Khadke S; Roces CB; Stone P
    Methods Mol Biol; 2017; 1494():127-144. PubMed ID: 27718190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scale-Independent Microfluidic Production of Cationic Liposomal Adjuvants and Development of Enhanced Lymphatic Targeting Strategies.
    Roces CB; Khadke S; Christensen D; Perrie Y
    Mol Pharm; 2019 Oct; 16(10):4372-4386. PubMed ID: 31437396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.
    Watson DS; Endsley AN; Huang L
    Vaccine; 2012 Mar; 30(13):2256-72. PubMed ID: 22306376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in vaccine delivery systems.
    O'Hagan DT
    Curr Drug Targets Infect Disord; 2001 Nov; 1(3):273-86. PubMed ID: 12455401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in vaccine adjuvants.
    Singh M; O'Hagan DT
    Pharm Res; 2002 Jun; 19(6):715-28. PubMed ID: 12134940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
    Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
    Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres.
    Kirby DJ; Rosenkrands I; Agger EM; Andersen P; Coombes AG; Perrie Y
    J Drug Target; 2008 Aug; 16(7):543-54. PubMed ID: 18686124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
    Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
    Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
    Khademi F; Taheri RA; Momtazi-Borojeni AA; Farnoosh G; Johnston TP; Sahebkar A
    Rev Physiol Biochem Pharmacol; 2018; 175():47-69. PubMed ID: 29700609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.
    Zhuang Y; Ma Y; Wang C; Hai L; Yan C; Zhang Y; Liu F; Cai L
    J Control Release; 2012 Apr; 159(1):135-42. PubMed ID: 22226776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of size on particulate vaccine adjuvants.
    Shah RR; O'Hagan DT; Amiji MM; Brito LA
    Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine approaches for antigen capture by liposomes.
    Zhou S; Luo Y; Lovell JF
    Expert Rev Vaccines; 2023; 22(1):1022-1040. PubMed ID: 37878481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.